189 related articles for article (PubMed ID: 23088940)
1. Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model.
Jia J; Yao W; Amugongo S; Shahnazari M; Dai W; Lay YA; Olvera D; Zimmermann EA; Ritchie RO; Li CS; Alliston T; Lane NE
Bone; 2013 Jan; 52(1):424-32. PubMed ID: 23088940
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
Exp Anim; 2006 Jul; 55(4):357-67. PubMed ID: 16880683
[TBL] [Abstract][Full Text] [Related]
3. Expression of TGF-β1 in the blood during fracture repair in an estrogen-deficient rat model.
Estai MA; Suhaimi F; Das S; Shuid AN; Mohamed Z; Soelaiman IN
Clinics (Sao Paulo); 2011; 66(12):2113-9. PubMed ID: 22189738
[TBL] [Abstract][Full Text] [Related]
4. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):1-8. PubMed ID: 16637224
[TBL] [Abstract][Full Text] [Related]
5. Prolonged use of alendronate alters the biology of cranial repair in estrogen-deficient rats' associated simultaneous immunohistochemical expression of TGF-β1+, α-ER+, and BMPR1B.
Giovanini AF; de Sousa Passoni GN; Göhringer I; Deliberador TM; Zielak JC; Storrer CLM; Costa-Casagrande TA; Scariot R
Clin Oral Investig; 2018 Jun; 22(5):1959-1971. PubMed ID: 29197953
[TBL] [Abstract][Full Text] [Related]
6. Local treatment of osteoporosis with alendronate-loaded calcium phosphate cement.
Zhao J; Tang H; Wang J; Li G
Chin Med J (Engl); 2014; 127(22):3906-14. PubMed ID: 25421189
[TBL] [Abstract][Full Text] [Related]
7. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
8. Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition.
Taylor EA; Donnelly E; Yao X; Johnson ML; Amugongo SK; Kimmel DB; Lane NE
Calcif Tissue Int; 2020 Mar; 106(3):303-314. PubMed ID: 31784772
[TBL] [Abstract][Full Text] [Related]
9. Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents.
Shahnazari M; Yao W; Wang B; Panganiban B; Ritchie RO; Hagar Y; Lane NE
J Bone Miner Res; 2011 Mar; 26(3):569-81. PubMed ID: 20839286
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
11. TGF-β1 Improves Biomechanical Strength by Extracellular Matrix Accumulation Without Increasing the Number of Tenogenic Lineage Cells in a Rat Rotator Cuff Repair Model.
Arimura H; Shukunami C; Tokunaga T; Karasugi T; Okamoto N; Taniwaki T; Sakamoto H; Mizuta H; Hiraki Y
Am J Sports Med; 2017 Aug; 45(10):2394-2404. PubMed ID: 28586631
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Hu S; Liu CC; Chen G; Willett T; Young RN; Grynpas MD
Osteoporos Int; 2016 Feb; 27(2):797-808. PubMed ID: 26272313
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of mesenchymal stem cells to the bone.
Yao W; Lane NE
Bone; 2015 Jan; 70():62-5. PubMed ID: 25173607
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses.
Mohsenifar Z; Fridoni M; Ghatrehsamani M; Abdollahifar MA; Abbaszadeh H; Mostafavinia A; Fallahnezhad S; Asghari M; Bayat S; Bayat M
Lasers Med Sci; 2016 May; 31(4):721-32. PubMed ID: 26964799
[TBL] [Abstract][Full Text] [Related]
15. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
Wang Y; Huang P; Tang PF; Chan KM; Li G
J Orthop Surg Res; 2011 Jul; 6():34. PubMed ID: 21752290
[TBL] [Abstract][Full Text] [Related]
16. Reversing bone loss by directing mesenchymal stem cells to bone.
Yao W; Guan M; Jia J; Dai W; Lay YA; Amugongo S; Liu R; Olivos D; Saunders M; Lam KS; Nolta J; Olvera D; Ritchie RO; Lane NE
Stem Cells; 2013 Sep; 31(9):2003-14. PubMed ID: 23818248
[TBL] [Abstract][Full Text] [Related]
17. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Luo Y; Zhang L; Wang WY; Hu QF; Song HP; Su YL; Zhang YZ
Bone; 2013 Aug; 55(2):439-48. PubMed ID: 23500174
[TBL] [Abstract][Full Text] [Related]
18. Effects of alendronate on lumbar intervertebral disc degeneration with bone loss in ovariectomized rats.
Song H; Luo Y; Wang W; Li S; Yang K; Dai M; Shen Y; Zhang Y; Zhang L
Spine J; 2017 Jul; 17(7):995-1003. PubMed ID: 28288923
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
Sakai S; Endo K; Takeda S; Mihara M; Shiraishi A
Bone; 2012 May; 50(5):1054-63. PubMed ID: 22366400
[TBL] [Abstract][Full Text] [Related]
20. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
